Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
Fu-Long Wang, Xiao-Li Wei, F.-H. Wang, N. Xu +21 more

